Clarius Group LLC Has $359,000 Stock Position in Edwards Lifesciences Corporation $EW

Clarius Group LLC lowered its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 3.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,593 shares of the medical research company’s stock after selling 176 shares during the period. Clarius Group LLC’s holdings in Edwards Lifesciences were worth $359,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in EW. Brighton Jones LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $266,000. Merit Financial Group LLC grew its stake in Edwards Lifesciences by 93.4% during the first quarter. Merit Financial Group LLC now owns 10,793 shares of the medical research company’s stock worth $782,000 after purchasing an additional 5,212 shares during the period. Gateway Investment Advisers LLC grew its stake in Edwards Lifesciences by 2.9% during the first quarter. Gateway Investment Advisers LLC now owns 11,917 shares of the medical research company’s stock worth $864,000 after purchasing an additional 336 shares during the period. Wedmont Private Capital grew its stake in Edwards Lifesciences by 18.1% during the first quarter. Wedmont Private Capital now owns 9,860 shares of the medical research company’s stock worth $684,000 after purchasing an additional 1,512 shares during the period. Finally, Farther Finance Advisors LLC grew its stake in Edwards Lifesciences by 390.7% in the first quarter. Farther Finance Advisors LLC now owns 8,808 shares of the medical research company’s stock valued at $633,000 after acquiring an additional 7,013 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Piper Sandler raised their price objective on Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, July 25th. Robert W. Baird raised their price objective on Edwards Lifesciences from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Friday, July 25th. Mizuho raised their price objective on Edwards Lifesciences from $87.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. BTIG Research raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Tuesday, July 29th. Finally, Royal Bank Of Canada raised their price objective on Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.61.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 0.6%

Shares of NYSE:EW opened at $76.59 on Tuesday. The stock has a market cap of $44.97 billion, a price-to-earnings ratio of 11.02, a PEG ratio of 3.71 and a beta of 1.05. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00. The business’s 50 day moving average is $78.46 and its 200 day moving average is $76.05.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.